PTK2B and Hepatic fibrosis: Administration of CCl4 in 6 weeks resulted in liver fibrosis, while co-administration of CCl4 and PF-431396, a dual pharmacological inhibitor of FAK and PYK2, significantly suppressed such liver injuries (Fig. 1A).